IGF-1R antisense oligodeoxynucleotide-treated autologous glioma cells IGV-001

{
  "id": "MLC-T-ONC-014334",
  "term": "IGF-1R antisense oligodeoxynucleotide-treated autologous glioma cells IGV-001",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of irradiated autologous glioma cells treated ex vivo with IMV-001, an antisense oligodeoxynucleotide of insulin-like growth factor receptor 1 (IGF-1R/AS ODN), and encapsulated within bio-diffusion chambers, with potential antineoplastic activity. The IGF-1R/AS ODN IMV-001-treated autologous glioma cells IGV-001 are encapsulated within implantable and removable bio-diffusion chambers with additional IMV-001, irradiated, and implanted into the patient. The IGF-1R/AS ODN binds to IGF-1R mRNA in glioma cells, and shuts down the translation of IGF-1R in the glioma cells. Downregulation of IGF-1R, in addition to irradiation, induces apoptosis and causes the release of exosomes, which contain tumor-associated antigens (TAAs). The diffusion of exosomes together with the additional IMV-001 from the bio-diffusion chambers may activate the patient's immune system and mount a cytotoxic T-lymphocyte (CTL) response against cells expressing these TAAs. IGF-1R, a receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and is essential for tumor cell growth, transformation and survival.",
  "synonyms": [
    "IGF-1R/AS ODN-treated autologous glioma cells IGV-001"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/igf-1r-antisense-oligodeoxynucleotide-treated-autologous-glioma-cells-igv-001/"
}